Selvigaltin (GB1211), an orally offered small molecule galectin-3 inhibitor formulated as being a treatment method for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and basic safety to deal with regulatory specifications. Inhibition of galectin-3 with GB1211 was not linked to any https://edwardx110jue3.blog5star.com/profile